The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease

Lisa Evans Dewald, Julie Dyall, Jennifer M. Sword, Lisa Torzewski, Huanying Zhou, Elena Postnikova, Erin Kollins, Isis Alexander, Robin Gross, Yu Cong, Dawn M. Gerhardt, Reed F. Johnson, Gene G. Olinger, Michael R. Holbrook, Lisa E. Hensley, Peter B. Jahrling

Research output: Contribution to journalArticlepeer-review

Abstract

No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridils broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.

Original languageEnglish (US)
Pages (from-to)S588-S591
JournalJournal of Infectious Diseases
Volume218
DOIs
StatePublished - Nov 22 2018
Externally publishedYes

Keywords

  • antiviral
  • bepridil
  • Marburg virus.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease'. Together they form a unique fingerprint.

Cite this